Platelet antagonists in migraine prophylaxis. A clinical trial using aspirin and dipyridamole

B. E. Masel, A. L. Chesson, B. H. Peters, H. S. Levin, J. B. Alperin

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The platelet hyperaggregability of the migraine population has lead us to postulate that platelet antagonists might be effective in migraine prophylaxis. A double-blind cross-over study of aspirin, 325 mg BID, combined with dipyridamole, 25 mg TID, compared to placebo and pretreatment conditions was undertaken. Platelet aggregation studies were done during the three month active medication and placebo periods. In patients with platelet hyperaggregability significant improvement occurred in headache frequency, intensity, and limitation of activity with no change in headache duration. Regardless of platelet aggregability, the 25 patients comprising the total sample significantly improved as compared to placebo. Sixty-eight percent of the patients tested reported subjective improvement while taking the active medication. No side effects related to the medication were reported and no patients, including those who withdrew from the study for other reasons, reported worsening of headache while on the active medication. Although the significance of platelet hyperaggregability in migraine patients, and the pharmacological effect of aspirin and dipyridamole on this, is unclear, these medications may have potentials as a method of migraine prophylaxis.

Original languageEnglish (US)
Pages (from-to)13-18
Number of pages6
JournalHeadache
Volume20
Issue number1
DOIs
StatePublished - 1980
Externally publishedYes

Fingerprint

Dipyridamole
Platelet Aggregation Inhibitors
Migraine Disorders
Aspirin
Clinical Trials
Blood Platelets
Headache
Placebos
Platelet Aggregation
Cross-Over Studies
Pharmacology
Population

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Platelet antagonists in migraine prophylaxis. A clinical trial using aspirin and dipyridamole. / Masel, B. E.; Chesson, A. L.; Peters, B. H.; Levin, H. S.; Alperin, J. B.

In: Headache, Vol. 20, No. 1, 1980, p. 13-18.

Research output: Contribution to journalArticle

Masel, B. E. ; Chesson, A. L. ; Peters, B. H. ; Levin, H. S. ; Alperin, J. B. / Platelet antagonists in migraine prophylaxis. A clinical trial using aspirin and dipyridamole. In: Headache. 1980 ; Vol. 20, No. 1. pp. 13-18.
@article{46e9b3fcce8b43d3a4fd637caf9b91bd,
title = "Platelet antagonists in migraine prophylaxis. A clinical trial using aspirin and dipyridamole",
abstract = "The platelet hyperaggregability of the migraine population has lead us to postulate that platelet antagonists might be effective in migraine prophylaxis. A double-blind cross-over study of aspirin, 325 mg BID, combined with dipyridamole, 25 mg TID, compared to placebo and pretreatment conditions was undertaken. Platelet aggregation studies were done during the three month active medication and placebo periods. In patients with platelet hyperaggregability significant improvement occurred in headache frequency, intensity, and limitation of activity with no change in headache duration. Regardless of platelet aggregability, the 25 patients comprising the total sample significantly improved as compared to placebo. Sixty-eight percent of the patients tested reported subjective improvement while taking the active medication. No side effects related to the medication were reported and no patients, including those who withdrew from the study for other reasons, reported worsening of headache while on the active medication. Although the significance of platelet hyperaggregability in migraine patients, and the pharmacological effect of aspirin and dipyridamole on this, is unclear, these medications may have potentials as a method of migraine prophylaxis.",
author = "Masel, {B. E.} and Chesson, {A. L.} and Peters, {B. H.} and Levin, {H. S.} and Alperin, {J. B.}",
year = "1980",
doi = "10.1111/j.1526-4610.1980.hed2001013.x",
language = "English (US)",
volume = "20",
pages = "13--18",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Platelet antagonists in migraine prophylaxis. A clinical trial using aspirin and dipyridamole

AU - Masel, B. E.

AU - Chesson, A. L.

AU - Peters, B. H.

AU - Levin, H. S.

AU - Alperin, J. B.

PY - 1980

Y1 - 1980

N2 - The platelet hyperaggregability of the migraine population has lead us to postulate that platelet antagonists might be effective in migraine prophylaxis. A double-blind cross-over study of aspirin, 325 mg BID, combined with dipyridamole, 25 mg TID, compared to placebo and pretreatment conditions was undertaken. Platelet aggregation studies were done during the three month active medication and placebo periods. In patients with platelet hyperaggregability significant improvement occurred in headache frequency, intensity, and limitation of activity with no change in headache duration. Regardless of platelet aggregability, the 25 patients comprising the total sample significantly improved as compared to placebo. Sixty-eight percent of the patients tested reported subjective improvement while taking the active medication. No side effects related to the medication were reported and no patients, including those who withdrew from the study for other reasons, reported worsening of headache while on the active medication. Although the significance of platelet hyperaggregability in migraine patients, and the pharmacological effect of aspirin and dipyridamole on this, is unclear, these medications may have potentials as a method of migraine prophylaxis.

AB - The platelet hyperaggregability of the migraine population has lead us to postulate that platelet antagonists might be effective in migraine prophylaxis. A double-blind cross-over study of aspirin, 325 mg BID, combined with dipyridamole, 25 mg TID, compared to placebo and pretreatment conditions was undertaken. Platelet aggregation studies were done during the three month active medication and placebo periods. In patients with platelet hyperaggregability significant improvement occurred in headache frequency, intensity, and limitation of activity with no change in headache duration. Regardless of platelet aggregability, the 25 patients comprising the total sample significantly improved as compared to placebo. Sixty-eight percent of the patients tested reported subjective improvement while taking the active medication. No side effects related to the medication were reported and no patients, including those who withdrew from the study for other reasons, reported worsening of headache while on the active medication. Although the significance of platelet hyperaggregability in migraine patients, and the pharmacological effect of aspirin and dipyridamole on this, is unclear, these medications may have potentials as a method of migraine prophylaxis.

UR - http://www.scopus.com/inward/record.url?scp=0018835952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018835952&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.1980.hed2001013.x

DO - 10.1111/j.1526-4610.1980.hed2001013.x

M3 - Article

VL - 20

SP - 13

EP - 18

JO - Headache

JF - Headache

SN - 0017-8748

IS - 1

ER -